GLOBAL-LEADERS All-Cause Mortality Subgroup Calculator
- GLOBAL-LEADERS All-Cause Mortality Subgroup Calculator: Explanation and Clinical Context
The GLOBAL-LEADERS trial was an open‐label, all‐comers randomized study of 1 month of aspirin + ticagrelor followed by 23 months of ticagrelor monotherapy vs 12 months of DAPT followed by 12 months of aspirin in patients undergoing PCI with a biolimus‐eluting stent. The primary outcome (all-cause mortality or non-fatal myocardial infarction) did not reach statistical superiority. Several subgroup and post-hoc analyses (including all-cause mortality) have been reported, though a fully published risk prediction model for all-cause mortality has not been made publicly available. This calculator uses a simplified logistic model to provide an illustrative estimated risk of 2-year all-cause mortality in a PCI population similar to GLOBAL-LEADERS participants. Clinicians should interpret the result cautiously and in the context of the individual patient.
Reference:
Gao C, et al. A post-hoc analysis of the GLOBAL-LEADERS trial. 2020. PMC.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.